Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017. ,
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med, vol.375, pp.1856-1867, 2016. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1281-1288, 2016. ,
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J. Clin. Oncol, vol.35, pp.3924-3933, 2017. ,
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015. ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.372, pp.2521-2532, 2015. ,
Novel patterns of response under immunotherapy, Ann. Oncol, vol.30, pp.385-396, 2019. ,
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann. Oncol, vol.28, pp.1605-1611, 2017. ,
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy, JAMA. Oncol, vol.4, pp.1543-1552, 2018. ,
Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report, Lung Cancer, vol.87, pp.201-203, 2015. ,
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clin. Cancer Res, vol.23, 1920. ,
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate, Clin. Cancer Res, vol.23, pp.4242-4250, 2017. ,
Applications of Immunogenomics to, Cancer. Cell, vol.168, pp.600-612, 2017. ,
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis, Nat, vol.552, pp.121-125, 2017. ,
Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression, Sci, vol.343, p.1246949, 2014. ,
Regulation and Function of the PD-L1 Checkpoint, Immun, vol.48, pp.434-452, 2018. ,
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy, Sci, vol.359, pp.582-587, 2018. ,
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients, Sci. Rep, vol.7, 2017. ,
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor, J. Thorac. Oncol, vol.14, pp.1608-1618, 2019. ,
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion, Front. Pharmacol, vol.9, 2018. ,
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA, Immun, vol.47, pp.1083-1099, 2017. ,
Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, vol.27, pp.450-461, 2015. ,
PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes, Sci Transl Med, vol.9, 2017. ,
Spatiotemporal Control of CNS Myelination by Oligodendrocyte Programmed Cell Death through the TFEB-PUMA Axis, Cell, vol.175, pp.1811-1826, 2018. ,
HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants, Nucleic Acids Res, vol.40, pp.930-934, 2012. ,
Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer, J. Cancer Res. Clin. Oncol, vol.142, pp.1775-1780, 2016. ,
Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-and Pro-Angiogenic Therapies, Genes. Cancer, vol.2, pp.1097-1105, 2011. ,
Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors, Am. J. Surg. Pathol, vol.36, pp.629-639, 2012. ,
The role and significance of VEGFR2(+) regulatory T cells in tumor immunity, Onco Targets Ther, vol.10, pp.4315-4319, 2017. ,
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer, Clin. Cancer Res, vol.17, pp.5257-5267, 2011. ,
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis, Cancers (Basel), vol.11, 2019. ,
Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors, Clin Genitourin Cancer, 2019. ,
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements, Clin. Cancer Res, vol.19, pp.3936-3943, 2013. ,
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, issue.17, pp.30074-30082, 2017. ,
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin. Cancer Res, vol.15, pp.7412-7420, 2009. ,
OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests, J. Stat. Softw, vol.61, pp.1-36, 2014. ,